NX210 is a patented peptide deduced from the thrombospondin repeat domains (TSRs) of the SCO-spondinThis is a first-in class multi-functional agent able to prevents neural cell death and to promote neurite outgrowth. Our data show that NX210 is able to promote neurite fasciculation and axonogenesis in a dose-dependent manner [1; 2] as well as to protect neurons against insults [3].

In vivo, NX210 has been shown to promote nerve fiber regrowth and the recovery of sensorimotor functions and in counteracting behavioral deficits in case of spinal cord injury (SCI) [3].

[1] Gobron et al. (2000) Glia. 32(2):177-91.
[2] Monnerie, H. et al. (1998) Cell Tissue Res 293(3): 407-18.
[3] Sakka L et al. (2014 ) PLoS One 25;9(3).

NX210 has been granted Orphan Drug Designation by European Medicine Agency (EMA) for the treatment of spinal cord injury and a Clinical Trial Application (CTA) for a phase I is now authorized by the french and belgian authorities. Our intent is to rapidly initiate this clinical trial for this indication.

In vivo regrowth of nerve fibers through the lesion site

60% of NX210 treated rats recover weight support and fore-hindlimb coordination (bbb >14)

Percentage of rats with a BBB score > 14 along the delay post NX210 treatment

BBB (Basso, Beattie and Bresnahan) Scoring is the reference method used to assess the motor function of rats. BBB over 14 means the return of toe clearance during stepping, predominant paw position, trunk stability, and tail position.